An older age, the male gender, and genetic variations such as patatin-like phospholipase domain-containing protein 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), glucokinase regulator (GCKR), membrane-bound O-acyltransferase domain-containing 7 (MBOAT7), myeloid–epithelial–reproductive tyrosine kinase (MERTK), and hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) are considered non-modifiable risk factors of MASLD [9]. Here, TM6SF2 is linked to metabolic dysfunction-associated steatotic liver disease.